Should you buy this healthcare company after its 39% fall?

This healthcare stock has endured a tough year, but is now the time to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Oxford BioMedica (LSE: OXB) have slumped by 39% since the turn of the year. They’re down by a further 6% today following an update. It provides clues as to whether now is a good time to buy it, or whether investors should buy a slice of healthcare sector peer GlaxoSmithKline (LSE: GSK) instead.

Oxford BioMedica’s results for the six months to 30 June show that the company is making encouraging progress. Its contract with Novartis is progressing well and contributed to 184% growth in sales during the period. There are also multiple confirmed purchase orders through to the second quarter of 2017 and Oxford BioMedica’s capacity expansion of its bioprocessing and laboratory facilities are now complete.

A collaboration with Green Cross LabCell has also been signed. This will identify and develop gene modified natural killer (NK) cell-based therapeutics. Green Cross has also taken an equity stake in Oxford BioMedica as part of a £10m placing. The funds will be used to progress its discovery and pre-clinical projects, as well as develop valuable intellectual property relating to the LentiVector platform.

Looking ahead, Oxford BioMedica is forecast to remain lossmaking in the next two years. As such, it would be unsurprising for there to be a further fundraising in the medium term following today’s placing announcement as well as the £7.5m placing in February 2016.

Lower risk?

Clearly, Oxford BioMedica has a bright long-term future and its strategy is sound. However, given the uncertainty faced by investors at the present time it may be prudent to buy stocks with lower risk profiles, but which also have excellent long-term growth prospects. One such company is GlaxoSmithKline, which is exceptionally well-diversified and is forecast to grow its bottom line over the next two years.

For example, GlaxoSmithKline’s earnings are due to rise by 27% in the current year and by a further 7% next year. This has the potential to boost investor sentiment – especially at a time when GlaxoSmithKline trades on a price-to-earnings (P/E) ratio of just 16.8. Its three-part business model also means that it has a very stable outlook compared to pharmaceutical peers. GlaxoSmithKline’s consumer goods division offers relative stability, while its vaccines and pharmaceutical potential is high due in part to its large and well-diversified product pipeline.

Of course, GlaxoSmithKline also offers a high yield. It stands at 5% at the present time, while Oxford BioMedica offers no dividend. This is understandable since Oxford BioMedica is a relatively small business focused on growth and in turning a profit in the near future. However, with cash returns and other asset classes offering disappointing income options, a 5% yield could prove to be popular among investors and may lead to high demand for GlaxoSmithKline’s shares over the coming years.

As such, while Oxford BioMedica has potential, GlaxoSmithKline is a much better buy right now. Its mix of growth potential, low risk and income return make it one of the most enticing stocks in the FTSE 350.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »